Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Transaction Price: £16.4900 per Ordinary Share
- Transaction Volume: 454.329 shares
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Dr. P J T Vallance, President of Pharmaceuticals R&D. This change resulted from the re-investment of dividends paid on July 14, 2016, under the Company's Deferred Investment Award Programme. No material changes to the company's overall financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a specific executive share transaction.
Investor Verification Checklist
- Verify the total shareholding of Dr. P J T Vallance following this transaction.
- Confirm the terms of the Deferred Investment Award Programme regarding dividend re-investment.
- Review the company's Form 20-F for comprehensive financial performance data, as this 6-K contains no aggregate financial results.